+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Middle East and Africa RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Molecule Type, Application, Route of Administration, and End User; and Country

  • PDF Icon

    Report

  • 117 Pages
  • December 2020
  • Region: Africa, Middle East
  • The Insight Partners
  • ID: 5236422
UP TO OFF until Jun 30th 2024
According to our new market research study on “Middle East & Africa RNAi Therapeutics Market to 2027 - Regional Analysis and Forecast - by Molecule Type, Route of Administration, Application, and End User,” the Middle East & Africa RNAi therapeutics market is expected to reach US$ 29.02 million by 2027 from US$ 16.76 million in 2019, it is estimated to grow at a CAGR of 7.2% from 2020 to 2027. The report provides trends prevailing in the Middle East & Africa RNAi therapeutics market and the factors driving the market growth along with those hindering it.

In 2019, the small interfering RNAs (siRNA) segment accounted for higher share of the market. Growth of this segment is attributed to increasing preference for small interfering RNAs for drug development and growing number of research partnerships. The microRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.

The growth of the Middle East & Africa RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and their benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region, which would eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in Middle East & Africa.

Benitec Biopharma; Olix Pharmaceuticals, Inc; GlaxoSmithKline plc; Alnylam Pharmaceuticals, Inc; and Arrowhead Pharmaceuticals, Inc are among the leading companies operating in the Middle East & Africa RNAi therapeutics market.

The report segments the Middle East & Africa RNAi therapeutics market as follows:

Middle East & Africa RNAi Therapeutics Market - by Molecule Type
  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

Middle East & Africa RNAi Therapeutics Market - by Route of Administration
  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

Middle East & Africa RNAi Therapeutics Market - by Application
  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

Middle East & Africa RNAi Therapeutics Market - by End User
  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories

Middle East & Africa RNAi Therapeutics Market - by Country
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Reasons to Buy
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA offshore pipeline market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the MEA offshore pipeline market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the offshore pipeline market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East & Africa RNAi Therapeutics Market - By Molecule Type
1.3.2 Middle East & Africa RNAi Therapeutics Market - By Application
1.3.3 Middle East & Africa RNAi Therapeutics Market - By Route of Administration
1.3.4 Middle East & Africa RNAi Therapeutics Market- By End User
1.3.5 Middle East & Africa RNAi Therapeutics Market - By Country
2. Middle East & Africa RNAi Therapeutics Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa RNAi Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 RNAi therapeutics Market - Middle East & Africa PEST Analysis
4.3 Expert Opinion
5. Middle East & Africa RNAi Therapeutics Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Growing Investments in RNAi Therapies
5.1.2 Rising Prevalence of Chronic Conditions and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost for RNAi Therapy Development
5.3 Market Opportunities
5.3.1 Significant Number of Pipeline Candidates for Strategic Alliances
5.4 Future Trends
5.4.1 Rising Emphasis on RNA Technologies
5.5 Impact analysis
6. RNAi Therapeutics Market - Middle East & Africa Analysis
6.1 Middle East & Africa RNAi Therapeutics Market Revenue Forecasts and Analysis
7. Middle East & Africa RNAi Therapeutics Market Analysis and Forecasts To 2027 - By Molecule Type
7.1 Overview
7.2 Middle East & Africa RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
7.2.1 Middle East & Africa RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)
7.3 Small Interfering RNAs (siRNA)
7.3.1 Overview
7.3.2 Middle East & Africa Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)
7.4 MicroRNA (miRNA)
7.4.1 Overview
7.4.2 Middle East & Africa MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
8. Middle East & Africa RNAi therapeutics Market Analysis and Forecasts To 2027 - By Application
8.1 Overview
8.2 Middle East & Africa RNAi therapeutics Market, By Application 2019 & 2027 (%)
8.2.1 Middle East & Africa RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Genetic Disorders
8.3.1 Overview
8.3.2 Middle East & Africa Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Oncology
8.4.1 Overview
8.4.2 Middle East & Africa Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Neurodegenerative Disorders
8.5.1 Overview
8.5.2 Middle East & Africa Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Cardiovascular Disorders
8.6.1 Overview
8.6.2 Middle East & Africa Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Middle East & Africa Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Infectious Diseases
8.8.1 Overview
8.8.2 Middle East & Africa Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.9 Renal Diseases
8.9.1 Overview
8.9.2 Middle East & Africa Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.10 Other Disorders
8.10.1 Overview
8.10.2 Middle East & Africa Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
9. Middle East & Africa RNAi therapeutics Market Analysis and Forecasts To 2027 - By Route of Administration
9.1 Overview
9.2 Middle East & Africa RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
9.2.1 Middle East & Africa RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
9.3 Intradermal Injections
9.3.1 Overview
9.3.2 Middle East & Africa Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Pulmonary Delivery
9.4.1 Overview
9.4.2 Middle East & Africa Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Intravenous Injections
9.5.1 Overview
9.5.2 Middle East & Africa Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Intraperitoneal Injections
9.6.1 Overview
9.6.2 Middle East & Africa Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Other Route of Administrations
9.7.1 Overview
9.7.2 Middle East & Africa Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Middle East & Africa RNAi Therapeutics Market Analysis - By End-User
10.1 Overview
10.2 Middle East & Africa RNAi Therapeutics Market, By End-User 2019-2027 (%)
10.2.1 Middle East & Africa RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)
10.3 Diagnostic Laboratories
10.3.1 Overview
10.3.2 Middle East & Africa Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Research and Academic Laboratories
10.4.1 Overview
10.4.2 Middle East & Africa Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Hospitals
10.5.1 Overview
10.5.2 Middle East & Africa Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
11. RNAi therapeutics Market Revenue and Forecasts To 2027 - Geographical Analysis
11.1 Middle East & Africa: RNAi Therapeutics Market
11.1.1 Overview
11.1.2 Middle East & Africa: RNAi Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
11.1.3 Middle East & Africa: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.4 Middle East & Africa RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
11.1.5 Middle East & Africa: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.6 Middle East & Africa RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
11.1.7 Middle East & Africa: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
11.1.8 Saudi Arabia: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.8.1 Saudi Arabia: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.8.2 Saudi Arabia: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.8.3 Saudi Arabia RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
11.1.8.4 Saudi Arabia: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.8.5 Saudi Arabia RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
11.1.9 UAE: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.9.1 UAE: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.9.2 UAE: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.9.3 UAE RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
11.1.9.4 UAE: RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.9.5 UAE RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
11.1.10 South Africa: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.10.1 South Africa: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.10.2 South Africa: RNAi Therapeutics Market, by Molecule Type, 2018-2027 (USD Million)
11.1.10.3 South Africa RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
11.1.10.4 South Africa RNAi Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
11.1.10.5 South Africa RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
12. Impact of COVID-19 Pandemic on Middle East & Africa RNAi therapeutics Market
12.1 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1 Benitec Biopharma
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Olix Pharmaceuticals, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms
List of Tables
Table 1. Middle East & Africa RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)
Table 2. Middle East & Africa RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. Middle East & Africa RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 4. Middle East & Africa RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)
Table 5. Middle East & Africa RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 6. Middle East & Africa RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 7. Middle East & Africa RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 8. Middle East & Africa RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 9. Saudi Arabia RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 10. Saudi Arabia RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 11. Saudi Arabia RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 12. Saudi Arabia RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 13. UAE RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 14. UAE RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 15. UAE RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 16. UAE RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 17. South Africa RNAi Therapeutics Market, by Molecule Type - Revenue and Forecast to 2027 (USD Million)
Table 18. South Africa RNAi Therapeutics Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 19. South Africa RNAi Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 20. South Africa RNAi Therapeutics Market, by End User - Revenue and Forecast to 2027 (USD Million)
Table 21. Glossary of Terms, RNAi Therapeutics Market
List of Figures
Figure 1. RNAi Therapeutics Market Segmentation
Figure 2. Middle East & Africa RNAi Therapeutics Market Overview
Figure 3. Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market
Figure 4. UAE is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Middle East & Africa RNAi Therapeutics Market - Leading Country Markets (US$ Mn)
Figure 6. RNAi Therapeutics Market - Middle East & Africa PEST Analysis
Figure 7. RNAi Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Middle East & Africa RNAi Therapeutics Market - Revenue Forecasts and Analysis - 2019- 2027
Figure 9. Middle East & Africa RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
Figure 10. Middle East & Africa Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Middle East & Africa MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Middle East & Africa RNAi therapeutics Market, By Application 2019 & 2027 (%)
Figure 13. Middle East & Africa Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Middle East & Africa Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Middle East & Africa Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Middle East & Africa Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Middle East & Africa Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Middle East & Africa Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Middle East & Africa Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Middle East & Africa Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Middle East & Africa RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
Figure 22. Middle East & Africa Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Middle East & Africa Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Middle East & Africa Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Middle East & Africa Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Middle East & Africa Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Middle East & Africa RNAi Therapeutics Market, by End-User 2019 & 2027 (%)
Figure 28. Middle East & Africa Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Middle East & Africa Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. Middle East & Africa Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 31. Middle East & Africa: RNAi Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
Figure 32. Middle East & Africa RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 33. Middle East & Africa: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)
Figure 34. Saudi Arabia: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 35. UAE: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 36. South Africa: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 37. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Benitec Biopharma
  • GlaxoSmithKline plc
  • Olix Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.